Medtronic expanded CE-marked indications for its Affera mapping and ablation platform by adding the Sphere-9 catheter for treatment of ventricular arrhythmias, including ventricular tachycardia and premature ventricular complexes. The broader approval widens the device’s market beyond atrial fibrillation and adds procedural options for electrophysiology centers in Europe. The update supports Medtronic’s stated goal to deepen penetration in electrophysiology through expanded labeling for its platform hardware and catheter ecosystem.